Angioedema Spotlight: A Closer Examination of Sacubitril/Valsartan Safety Results

References

1. 1.↵
   1. McMurray JJ,
   2. Packer M,
   3. Desai AS,
   4. et al

   . Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Fryer RM,
   2. Segreti J,
   3. Banfor PN

   . Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol 2008;153:947–55.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Kostis JB,
   2. Packer M,
   3. Black HR,
   4. Schmieder R,
   5. Henry D,
   6. Levy E

   . Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial. Am J Hypertens 2004;17:103–11.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Gu J,
   2. Noe A,
   3. Chandra P,
   4. et al

   . Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010;50:401–14.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Toh S,
   2. Reichman ME,
   3. Houstoun M,
   4. et al

   . Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med 2012;172:1582–9.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Solomon SD,
   2. Zile M,
   3. Pieske B,
   4. et al

   . The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012;380:1387–95.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Senni M,
   2. McMurray JJ,
   3. Wachter R,
   4. et al

   . Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail 2016;18:1193–202.

   OpenUrl
8. 8.↵
   Center for Drug Evaluation and Research. Application number 207620Orig1s000. Medical review(s): LCZ696 (Entresto). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207620Orig1s000MedR.pdf. Accessed 29 Aug 2016.
9. 9.↵
   1. Yancy CW,
   2. Jessup M,
   3. Bozkurt B,
   4. et al

   . 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2016;68:1476–88.

   OpenUrlFREE Full Text